Canada markets closed

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
129.52-2.44 (-1.85%)
At close: 04:00PM EDT
129.49 -0.03 (-0.02%)
After hours: 07:01PM EDT

BeiGene, Ltd.

94 Solaris Avenue
Camana Bay
Grand Cayman KY1-1108
Cayman Islands
345 949 4123
https://www.beigene.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees10,600

Key Executives

NameTitlePayExercisedYear Born
Mr. John V. OylerCo-Founder, Executive Chairman & CEO2.05MN/A1968
Dr. Xiaobin Wu Ph.D.President & COO1.69MN/A1962
Dr. Xiaodong Wang Ph.D.Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder250kN/A1963
Ms. Julia WangCFO & Principal Financial Officer964.2kN/A1972
Mr. Wang Lai Ph.D.Global Head of R&D996.92k9.13M1977
Mr. Titus B. BallVP & Chief Accounting OfficerN/AN/A1973
Ms. Liza HeapesHead of Investor RelationsN/AN/AN/A
Mr. Chan LeeGeneral Counsel & Senior VPN/AN/AN/A
Mr. Yang JiChief Compliance OfficerN/AN/AN/A
Dr. Yan QiSenior VP & Head of Public Affairs - Greater ChinaN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Corporate Governance

BeiGene, Ltd.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 9; Board: 5; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.